Zhigang Ma1, Jie Lian1, Ming Yang2, Jiazi Wuyang3, Ci Zhao4, Wenhao Chen5, Chao Liu1, Qi Zhao6, Changjie Lou1, Jiguang Han7, Yanqiao Zhang8. 1. Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150040, PR China. 2. Department of Colorectal Surgery, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100021, PR China. 3. Department of Biotherapy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150040, PR China. 4. Center of Oncology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei Province, PR China. 5. Peking University Sixth Hospital, Beijing, 100191, PR China. 6. Department of Endoscopy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150040, PR China. 7. Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150040, PR China. 8. Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150040, PR China. Electronic address: yanqiaozhang@ems.hrbmu.edu.cn.
Abstract
AIM: Arginase-1 (Arg-1) metabolizes l-arginine to l-ornithine and urea. It has been documented to have a role in various malignancies. However, the relationship between Arg-1 expression and clinicopathological characteristics of colorectal cancer (CRC) patients remains to be elucidated. The present study aimed to analyze the expression and prognostic value of Arg-1 in patients with CRC. MATERIAL AND METHODS: The mRNA and protein expressions of Arg-1 in fresh colorectal cancer tissue specimens and the corresponding noncancerous tissue specimens were examined by RT-qPCR (n = 24) and western blot analysis (n = 17). Arg-1 expression levels were determined in paraffin-embedded CRC tissue specimens (n = 236) by immunohistochemistry. The associations of Arg-1 expression and clinicopathological features and clinical prognosis in 236 CRC patients were analyzed. RESULTS: The expression levels of Arg-1 were significantly higher in the CRC tissues compared with the matched noncancerous tissues, and elevated Arg-1 expression was remarkably associated with stage III-IV tumors (P = 0.007), lymph node metastasis (P = 0.019) and a plasma albumin concentration <35 g/l (P = 0.022). Kaplan-Meier analysis indicated that Arg-1 overexpression was associated with adverse prognoses for overall survival (OS) (P < 0.001) and disease-free survival (DFS) (P < 0.001) in all cases. Further analysis revealed that the patients with high Arg-1 expression had significantly shorter OS and DFS at the advanced stages (III + IV) (P = 0.032 for OS, and P = 0.012 for DFS) but not at the early stages (I + II) (P = 0.194 for OS, and P = 0.065 for DFS). Multivariate analysis revealed that Arg-1 overexpression was an independent prognostic factor for OS (P = 0.002) and DFS (P < 0.001) in patients with CRC. CONCLUSION: The data indicated that Arg-1 overexpression in CRC may be a marker that can discriminate subgroups of patients with a poor prognosis.
AIM: Arginase-1 (Arg-1) metabolizes l-arginine to l-ornithine and urea. It has been documented to have a role in various malignancies. However, the relationship between Arg-1 expression and clinicopathological characteristics of colorectal cancer (CRC) patients remains to be elucidated. The present study aimed to analyze the expression and prognostic value of Arg-1 in patients with CRC. MATERIAL AND METHODS: The mRNA and protein expressions of Arg-1 in fresh colorectal cancer tissue specimens and the corresponding noncancerous tissue specimens were examined by RT-qPCR (n = 24) and western blot analysis (n = 17). Arg-1 expression levels were determined in paraffin-embedded CRC tissue specimens (n = 236) by immunohistochemistry. The associations of Arg-1 expression and clinicopathological features and clinical prognosis in 236 CRC patients were analyzed. RESULTS: The expression levels of Arg-1 were significantly higher in the CRC tissues compared with the matched noncancerous tissues, and elevated Arg-1 expression was remarkably associated with stage III-IV tumors (P = 0.007), lymph node metastasis (P = 0.019) and a plasma albumin concentration <35 g/l (P = 0.022). Kaplan-Meier analysis indicated that Arg-1 overexpression was associated with adverse prognoses for overall survival (OS) (P < 0.001) and disease-free survival (DFS) (P < 0.001) in all cases. Further analysis revealed that the patients with high Arg-1 expression had significantly shorter OS and DFS at the advanced stages (III + IV) (P = 0.032 for OS, and P = 0.012 for DFS) but not at the early stages (I + II) (P = 0.194 for OS, and P = 0.065 for DFS). Multivariate analysis revealed that Arg-1 overexpression was an independent prognostic factor for OS (P = 0.002) and DFS (P < 0.001) in patients with CRC. CONCLUSION: The data indicated that Arg-1 overexpression in CRC may be a marker that can discriminate subgroups of patients with a poor prognosis.
Authors: Leonard Angka; Christiano Tanese de Souza; Katherine E Baxter; Sarwat T Khan; Marisa Market; Andre B Martel; Lee-Hwa Tai; Michael A Kennedy; John C Bell; Rebecca C Auer Journal: Mol Ther Date: 2022-05-26 Impact factor: 12.910
Authors: Xinming Su; Yalin Xu; Gregory C Fox; Jingyu Xiang; Kristin A Kwakwa; Jennifer L Davis; Jad I Belle; Wen-Chih Lee; Wing H Wong; Francesca Fontana; Leonel F Hernandez-Aya; Takayuki Kobayashi; Helen M Tomasson; Junyi Su; Suzanne J Bakewell; Sheila A Stewart; Christopher Egbulefu; Partha Karmakar; Melisa A Meyer; Deborah J Veis; David G DeNardo; Gregory M Lanza; Samuel Achilefu; Katherine N Weilbaecher Journal: J Clin Invest Date: 2021-10-15 Impact factor: 14.808
Authors: Tomasz M Grzywa; Anna Sosnowska; Paweł Matryba; Zuzanna Rydzynska; Marcin Jasinski; Dominika Nowis; Jakub Golab Journal: Front Immunol Date: 2020-05-15 Impact factor: 7.561
Authors: Ioannis Karagiannidis; Eliane de Santana Van Vilet; Erika Said Abu Egal; Brandon Phinney; Damian Jacenik; Eric R Prossnitz; Ellen J Beswick Journal: Cancers (Basel) Date: 2020-10-06 Impact factor: 6.639
Authors: Barbora Pokrývková; Jana Šmahelová; Natálie Dalewská; Marek Grega; Ondřej Vencálek; Michal Šmahel; Jaroslav Nunvář; Jan Klozar; Ruth Tachezy Journal: Diagnostics (Basel) Date: 2021-03-31